Source Omega Home

Nutra India Summit Diabetes Nutraceutical Probiotics Talk

Kibow Biotech Founder is an Invited Speaker at the The 6th Nutra India Summit at the World Trade Centre, Mumbai.

Kibow Biotech, Inc., a US-based biotech firm that manufactures a probiotic nutraceutical supplement for patients with kidney failure, is pleased to announced that Dr. Ranganathan, VP (R&D) and interim CEO, has been invited to be a Speaker at The 6th Nutra India Summit.

Mumbai, Maharashtra, February 15, 2011 /India PRwire-- Kibow Biotech, Inc., a pioneering US-based biotech firm that manufactures a probiotic nutraceutical supplement for patients with kidney failure, is pleased to announced that Dr. Natarajan Ranganathan, VP (R&D) and interim CEO, has been invited to be a Speaker at The 6th Nutra India Summit. The Summit organised by Central Food Technological Research Institute (CFTRI), The Council for Scientific and Industrial Research (CSIR) and MM Activ (Sci-Tech Communication Company), is scheduled from February 15 to 18, 2011, at the World Trade Centre, Mumbai.

The title of Dr. Ranganathan's presentation is, "A Novel Approach for Uremic Toxin Removal Utilizing a Probiotics Dietary Supplement via "Enteric Dialysis™"

Dr. Natarajan Ranganathan, VP (R&D) and interim CEO of the Newtown Square, Pennsylvania, based company, said, Kibow Biotech is honored to have been invited to be a keynote speaker in the area of 'Nutrigenomics, Pre & Probiotics, & Enzyme.' Dr. Ranganathan stated that, "I am especially pleased to be sharing the stage with many prominent speakers, from the Nutra Food and Bio-Pharma industry."

The three-day event to be held at the World Trade Centre in Mumbai will have International Conference, Keynote Lectures, NuFFooDS - Products & Ingredients Expo, B2B meetings, CEO summit, Poster Competition, Doctors and Nutritionists Forum and Nutra Awards. Over 500 delegates are expected to participate in the event.

India is considered the diabetes capital of the world, with as many as 50 million people suffering from this chronic disease. Diabetes is the most common cause of kidney failure and even when diabetes is controlled, the disease can lead to CKD and kidney failure. It is with this thought in mind, that Dr. Rangan developed the product, Kibow® Biotics, which utilizes a patented and proprietary bowel-based enteric technology for use in clinical applications towards maintaining a healthy kidney function. This is also largely why Kibow is currently in the process of opening a subsidiary in India to make Kibow Biotics accessible here.

Dr. Ranganathan states, "By developing an affordable, readily available and easy-to-administer dietary supplement, Kibow offers hope to all those who suffer from kidney problems in the USA and other countries such as India in accordance with their respective governmental regulatory/registration authorities."

Notes to Editor

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow® Biotics," an orally consumable, enteric-coated Gel Cap product formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug, dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

Forward-looking statements:

Kibow®Biotics or any other dietary supplement is not intended to diagnose, treat, cure or prevent any disease as per the U.S. FDA. Kibow's website contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information on Dr. Scott Doughman: 

Post a comment (* required field)

Name *
Email *
Comments *
Anti-Spam Code

Please type the Anti-Spam code, seen on the image, into the text box below. This code is necessary to prevent spam.